Your SlideShare is downloading. ×
http://www.biospectrumasia.com/content/printArticle.asp
Bangalore, May 6, 2011: At the Bangalore INDIA BIO 2011, Dr. Renu ...
http://www.biospectrumasia.com/content/printArticle.asp
process are well thought of and one has to ensure that some prelim...
Upcoming SlideShare
Loading in...5
×

Finance and investment in Biopharma : Kapil Khandelwal, EquNev Capital, www.equnev.com

497

Published on

Kapil Khandelwal
EquNev Capital
www.equnev.com

Published in: Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
497
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Finance and investment in Biopharma : Kapil Khandelwal, EquNev Capital, www.equnev.com"

  1. 1. http://www.biospectrumasia.com/content/printArticle.asp Bangalore, May 6, 2011: At the Bangalore INDIA BIO 2011, Dr. Renu Swarup, adviser, Ministry of Science & Technology, said, "India should make more investments. The department of biotech was launched in 2007 and from then we have focused to establish it special organization that offers several innovative schemes. BIRAC is a separate organization which specializes in public opportunities and several small business have launched through the partnership route. We are also very supportive of proof of concepts and innovations. The concept was to encourage private-public partnership and government partnerships. The key objectives are to support early stages of BIPP (Bio technology industry partnership programme), support for the discovery and innovation, technology & product development." The topic for discussion was – Finance and Investments in Biotechnology. In the panel discussion chaired by Mr. Kapil Khandelwal - director, EquNev Capital, the other panelists were Dr. Shirshendu Mukherjee, strategic advisor, R&D Initiative India, Wellcome Trust , Dr. Purnima Sharma, managing director, Biotech Consortium, Dr. Sunny Sharma, senior managing director, Asia, OrbiMed Advisors, Dr. Krathish Bopanna - president & executive director, Semler Research Centre and Mr. Ravi Tyagi - head, SME Project, National Stock Exchange. Dr. Krathish Bopanna - President & Executive Director, Semler Research Centre said, “While raising funds there are many critical factors to consider namely - strategy, the landscape, expertise, sustainability. While doing the strategy we have to see whether the product is of domestic , national or of international interest. Whether we can fit many ideas and components together and also have a look at the risk factor." "We have to be clear with the direction of what we are doing? Whether we are repeating success or failures of the past. we should be clear in what we are doing. In partnership business if the partners have to completley understand the risk. A funding body will always look at an 80 percent of success rate. One must either have expertise in finance or must have a keen business acumen. We always need a 'driver' who understands us and a mentor to always guide. The three factors - Science, business and happiness are like a triangle one follows the other. When we chase one it will always lead to the other.” he added Dr. Purnima Sharma - managing director, Biotech Consortium, said, “Writing a proposal is like winning a game.” International funders are always particular of how a proposal is made. Firstly we should make sure that we are eligible for the proposal. Basic things like reading the instructions clearly or respond to all sections and cover all the topics. Leave nothing blank. When presenting a unique and original product it is important that the http://www.biospectrumasia.com/content/printArticle.asp (1 of 2) [09-05-2011 01:07:26] P R I N T
  2. 2. http://www.biospectrumasia.com/content/printArticle.asp process are well thought of and one has to ensure that some preliminary work is done regarding this idea. They should always be an element of innovation, novelty and a commercial potential." She aslo said, "If there's the element of invention to that technology then there should be clarity in terms of license and IP ownership on improvements or modifications that can be made." Dr. Shirshendu Mukherjee - strategic advisor- R&D Initiative India, Wellcome Trust , said, “Funding is not difficult in India if market is good then funds will be good. There are many divisions with-in, like science funding and funding for investments in technology transfer. We do not make portfolios but only do the funding.” Citing an example he said, “11.4 million of people die from infectious diseases. Funds for diagnostics and drugs addressing these infectious diseases are looked up on a priority.” Our goal is to foster and promote research with the aim of improving humanity and healthcare facilities” http://www.biospectrumasia.com/content/printArticle.asp (2 of 2) [09-05-2011 01:07:26] P R I N T

×